Dashboard
Manage Tickers

FDMT4D Molecular Therapeutics, ...

Nasdaq 4dmoleculartherapeutics.com


$ 23.61 $ -0.78 (-3.2 %)    

Friday, 14-Jun-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 23.63
$ 24.21
$ 0.00 x 0
$ 0.00 x 0
$ 23.53 - $ 24.21
$ 9.44 - $ 36.25
365,641
na
1.16B
$ 1.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-saturday-4dmt-presented-injection-free-subgroup-analyses-from-4d-150-phase-2-prism-randomized-dose-expansion-cohort-in-wet-amd-patients-with-severe-disease-activity--high-treatment-burden-at-the-clinical-trials-summit-2024
Reported Saturday, 4DMT Presented Injectio...
06/10/2024 07:23:18

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF inj...

4d-molecular-therapeutics-entered-into-a-sales-agreement-with-leerink-partners-pursuant-to-prospectus-supplement-relating-to-offering-co-may-sell-up-to-250m-of-common-stock
4D Molecular Therapeutics Entered Into A S...
06/07/2024 21:19:40

- SEC Filing

goldman-sachs-optimistic-about-regenxbios-gene-therapy-pipeline-sees-over-160-upside
Goldman Sachs Optimistic About Regenxbio's...
06/07/2024 18:30:54

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

analyst-expectations-for-4d-molecular-therapeuticss-future
Analyst Expectations For 4D Molecular Ther...
06/07/2024 15:00:39

hc-wainwright--co-reiterates-buy-on-4d-molecular-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on 4D M...
06/07/2024 13:46:39

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...

why-g-iii-apparel-shares-are-trading-lower-by-13-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why G-III Apparel Shares Are Trading Lower...
06/06/2024 17:39:18

why-is-4d-molecular-therapeutics-stock-trading-lower-on-thursday-genetic-disease-focused-study-data-released
Why Is 4D Molecular Therapeutics Stock Tra...
06/06/2024 16:43:13

4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease.

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
06/06/2024 16:31:11

4d-molecular-therapeutics-to-present-interim-phase-12-aerow-clinical-trial-data-at-47th-european-cystic-fibrosis-conference-says-showed-clinically-meaningful-improvements-in-ppfev1-at-12-months-in-2-of-3-participants
4D Molecular Therapeutics To Present Inter...
06/06/2024 11:36:02

4d-molecular-therapeutics-to-present-interim-data-from-aerosolized-4d-710-phase-12-aerow-clinical-trial-for-cystic-fibrosis-at-47-european-cystic-fibrosis-conference
4D Molecular Therapeutics To Present Inter...
05/30/2024 12:07:16

Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial ...

hc-wainwright--co-reiterates-buy-on-4d-molecular-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on 4D M...
05/13/2024 10:45:35

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...

4d-molecular-therapeutics-q1-2024-gaap-eps-066-beats-078-estimate
4D Molecular Therapeutics Q1 2024 GAAP EPS...
05/09/2024 21:16:02

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimat...

to-the-moon-a-look-inside-an-etf-focused-on-companies-at-the-cutting-edge-of-innovation
To The Moon! A Look Inside An ETF Focused ...
04/18/2024 18:29:09

rbc-capital-maintains-outperform-on-4d-molecular-therapeutics-raises-price-target-to-40
RBC Capital Maintains Outperform on 4D Mol...
04/15/2024 17:13:54

RBC Capital analyst Luca Issi maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price targe...

barclays-initiates-coverage-on-4d-molecular-therapeutics-with-overweight-rating-announces-price-target-of-45
Barclays Initiates Coverage On 4D Molecula...
04/15/2024 11:06:38

Barclays analyst Gena Wang initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight rating and announ...

bmo-capital-maintains-outperform-on-4d-molecular-therapeutics-lowers-price-target-to-63
BMO Capital Maintains Outperform on 4D Mol...
04/01/2024 16:18:10

BMO Capital analyst Kostas Biliouris maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and lowers the pric...

jefferies-maintains-buy-on-4d-molecular-therapeutics-raises-price-target-to-58
Jefferies Maintains Buy on 4D Molecular Th...
04/01/2024 14:49:55

Jefferies analyst Nalin Tejavibulya maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target...

4d-molecular-therapeutics-outlines-pivotal-development-plans-for-cystic-fibrosis-rare-inherited-disease
4D Molecular Therapeutics Outlines Pivotal...
03/28/2024 18:04:07

4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine...

4dmt-announces-update-on-regulatory-interactions-and-development-path-for-4d-710-for-treatment-of-cystic-fibrosis
4DMT Announces Update On Regulatory Intera...
03/28/2024 12:10:24

Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EM...

4d-molecular-therapeutics-stock-a-deep-dive-into-analyst-perspectives-5-ratings
4D Molecular Therapeutics Stock: A Deep Di...
03/01/2024 13:01:13

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)